Virtual Reality for Dementia

(VR-Care Trial)

Not yet recruiting at 1 trial location
AD
MB
Overseen ByMervin Blair, PhD
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

The goal of this feasibility clinical trial is to learn whether supervised virtual reality (VR) sessions can be safely and practically provided to adults aged 55 years and older with moderate-to-severe dementia who experience agitation while receiving care in inpatient geriatric psychiatry units.

The main questions this study aims to answer are:

Can participants be identified, enrolled, and retained in the study? Can participants tolerate and complete supervised VR sessions? Can clinical staff fit VR sessions into routine inpatient care? What safety or comfort concerns occur during or after VR sessions? Can the study team collect information needed to plan a larger future study?

Following informed consent, prospective participants will undergo screening to determine eligibility. Those who are eligible and enrolled will complete any remaining baseline assessments and will then be offered a brief VR familiarization or orientation procedure. Completion of tolerated familiarization is required before regular VR sessions may begin. Familiarization will not count as intervention initiation or as a regular VR intervention session. These activities form one continuous study period; there is no fixed observational or waiting period.

Participants who tolerate familiarization may be offered supervised VR sessions up to three times per week for up to six weeks, with a maximum of 18 regular sessions. Sessions will start at about 10 minutes and may increase gradually to about 30 minutes, depending on each participant's comfort and tolerance.

Familiarization and early VR exposure will begin with calming, low-stimulation, non-threatening virtual environments. Content may later be adjusted based on the participant's comfort, preferences, observed response, clinical appropriateness, and safety. Participants will remain seated and will be monitored by trained staff. Sessions will not start or will be stopped if the participant shows distress, discomfort, refusal, dizziness, nausea, confusion, worsening agitation, or any other safety concern.

Researchers will also collect information about agitation, behavioural symptoms, quality of life, medication use, staff experience, and workflow. This study is not designed to prove that VR treats agitation or dementia. The findings will be used to determine whether a larger future study is practical and how it should be designed.

Who Is on the Research Team?

LV

Lisa Van Bussel, MD - Geriatric Psychiatrist

Principal Investigator

St. Joseph's Health Care London - Finch Family Mental Health Care Building

TA

Tuoyo Awani, MD - Geriatric Psychiatrist

Principal Investigator

London Health Sciences Centre - Victoria Hospital

Are You a Good Fit for This Trial?

This trial is for adults aged 55 and older with moderate-to-severe dementia who experience agitation while staying in an inpatient geriatric psychiatry unit. Participants must be able to tolerate a brief VR orientation session before starting regular sessions.

Inclusion Criteria

I have been diagnosed with major neurocognitive disorder due to Alzheimer's or similar causes.
Moderate-to-severe dementia based on documented clinical diagnosis, clinical assessment, or available medical record information
Expected to remain admitted long enough to participate in some study procedures, with uncertain discharge timing allowed
See 6 more

Exclusion Criteria

I have severe vision problems that prevent me from using a VR headset safely.
I do not have delirium right now.
Clinically significant delusions and/or hallucinations that may increase risk of distress during VR exposure, including NPI-NH delusion and/or hallucination subscale score ≥4 or clinical equivalent
See 3 more

What Are the Treatments Tested in This Trial?

Interventions

  • Supervised Virtual Reality Sessions

Trial Overview

The study is testing whether supervised virtual reality (VR) sessions, up to three times per week for six weeks, are safe and practical for people with dementia-related agitation. Sessions use calming environments and are closely monitored by staff.

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: Supervised Virtual Reality InterventionExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Lead Sponsor

Trials
678
Recruited
421,000+